Supriya Lifescience Limited has informed the Exchange regarding a press release dated November 13, 2025, titled "Press Release for the Unaudited Financial Results for the Quarter and Half Year ended September 30, 2025".
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Supriya Lifescience has informed the stock exchange about a press release dated November 13, 2025, covering its unaudited financial results for the quarter and half year ended September 30, 2025. This is essentially a regulatory notification confirming that the company has shared its Q2 FY26 and H1 FY26 earnings update with the public via a press release. No specific revenue, profit, or margin figures are included in this particular filing — investors would need to refer to the actual press release or the detailed results filed with the exchange. The announcement signals the formal completion of the company's quarterly earnings disclosure process for the period.
This is a procedural disclosure rather than a material event, so direct stock price impact is unlikely. Investors should look at the actual unaudited numbers in the press release to gauge performance trends in the pharma/API segment.